TY - JOUR T1 - [Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: a population study]. AU - Sicras-Mainar,Antoni, AU - Font-Ramos,Beatriu, AU - Roldán-Suárez,Cecilia, AU - Navarro-Artieda,Ruth, AU - Ibáñez-Nolla,Jordi, Y1 - 2013/09/03/ PY - 2013/02/25/received PY - 2013/04/03/revised PY - 2013/04/06/accepted PY - 2013/9/7/entrez PY - 2013/9/7/pubmed PY - 2015/4/10/medline KW - Cardiovascular event KW - Compliance KW - Control KW - Costes sanitarios KW - Cumplimiento KW - Diabetes KW - Evento cardiovascular KW - Healthcare costs KW - Hipoglucemias KW - Hypoglycaemias SP - 557 EP - 69 JF - Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion JO - Endocrinol Nutr VL - 60 IS - 10 N2 - OBJECTIVES: To determine compliance, metabolic control, complications and healthcare costs of patients treated with metformin started a second antidiabetic drug in patients with type 2 diabetes (T2DM). PATIENTS AND METHODS: Design multicenter observational retrospective. Patients were evaluated ≥30 years (age), treated with metformin and started a second antidiabetic treatment during 2008-2009. There were 4 patient groups (metformin and another antidiabetic): a) dipeptidyl peptidase-4 inhibitors (IDPP4), b) sulfonylureas, c) glitazones and d) insulin. MAIN MEASURES: comorbidity, metabolic control, compliance and complications. Patients were followed for 2 years. The cost model differed direct health costs (primary care / specialist) and indirect (labor productivity). STATISTICAL ANALYSIS: logistic regression models and ANCOVA, p<0.05. RESULTS: 2067 patients were included (mean age: 66.6 years male: 53.1%). 25.1% started a second treatment with IDPP4; 42.9% sulfonylureas, 14.0% glitazones and 18.0% insulin. At 2 years follow-up, patients treated with IDPP4 showed greater adherence vs. 70.3%. 59.9%, 60.3% and 58.4; better control of 64.3% vs. DM2. 62.6%, 62.8% and 50.5% and a decrease of 13.9% compared to hypoglycaemia 40.4%, 37.6% and 58.9% respectively (p<0.001). The average / unit total costs was €2,321 vs. €2,475, €2,724 and €3,164, respectively, p<0.001. Rates of cardiovascular events and renal failure were 3.7%, 6.4%, 7.6% and 10.2% respectively. CONCLUSIONS: Sulfonylureas were the most commonly used drugs. Patients treated with IDPP4 had higher compliance and control of diabetes, with lower rates of hypoglycaemia and healthcare costs. SN - 1579-2021 UR - https://www.unboundmedicine.com/medline/citation/24008167/[Characterization_of_and_costs_associated_to_the_profile_of_patients_with_type_2_diabetes_treated_with_metformin_who_are_added_a_second_oral_antidiabetic_drug:_a_population_study]_ L2 - http://linkinghub.elsevier.com/retrieve/pii/S1575-0922(13)00181-2 DB - PRIME DP - Unbound Medicine ER -